Zim Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zim Laboratories reported a weak Q1 FY26 with consolidated revenue from operations falling about 12% year-on-year to Rs 7,175.61 lakhs from Rs 8,182.44 lakhs in Q1 FY25. The company swung to a consolidated loss before tax of Rs 243.20 lakhs (vs profit of Rs 123.44 lakhs) and a loss after tax of Rs 187.49 lakhs (vs profit of Rs 89.83 lakhs), translating to a negative EPS of Rs 0.38. Total expenses of Rs 7,566.44 lakhs were only modestly lower YoY, so higher relative costs drove the margin pressure. Standalone results also showed a loss after tax of Rs 169.19 lakhs versus a profit of Rs 75.90 lakhs in the year-ago quarter. Deloitte Haskins & Sells LLP has issued an unmodified limited review report on these results, though it noted that prior period figures had been reviewed by a different auditor, indicating a recent change in statutory auditor. The board also approved appointment of Protiviti India as internal auditor, an investment of up to AED 4,50,000 into step-down subsidiary ZIM Scientific Office L.L.C (a related party transaction), and the closure of ZIM Laboratories Middle East DMCC.
Shareholders should note a negative quarter with revenue contraction and a return to losses, which is likely to weigh on near-term sentiment. The auditor change, related-party investment into a newly formed subsidiary with nil turnover, and closure of a Dubai step-down subsidiary also warrant monitoring for governance and execution risks.